



**Jubilant Life Sciences Ltd.**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubl.com](http://www.jubl.com)

## **Jubilant Life Sciences receives ANDA approval for Itraconazole Capsules**

***Noida (UP), India, Monday, February 27, 2017***

Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for **Itraconazole Capsules, 100 mg**, the generic version of Sporanox® of Janssen Pharmaceuticals, which is used for the treatment of fungal infections.

The Company has received 8 approvals from the USFDA during the year. As on December 31, 2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved.

### **About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 6,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

### **For more information, please contact:**

#### ***For Investors***

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)  
[anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Ph: +91 22 6645 1209 / 1220  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)



*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*